Parkinson’s disease (PD) is a neurodegenerative brain disease that progressively leads to motor dysfunction and cognitive decline. It affects more than 10 million people worldwide.
Focused ultrasound has international and FDA approval to treat tremor-dominant PD and is being assessed to treat Parkinson’s dyskinesia, which is characterized by uncontrolled, involuntary movements of the face, arms, legs, or trunk. Focused ultrasound–induced blood-brain barrier opening and subsequent delivery of therapeutics may also have the potential to curb, or even reverse, the progression of the underlying disease.
As Parkinson's Awareness Month comes to a close, we are sharing important progress that has been made in the field, bringing hope to countless patients worldwide.
After first noticing symptoms in 2017, Rich Nagy underwent focused ultrasound therapy for Parkinson's disease in 2020. He has since been able to resume his hobbies, including playing the violin and boxing.
The field of focused ultrasound for Parkinson's disease is expanding rapidly as researchers widen the scope of possibilities, clinicians treat more patients, and sites launch clinical trials. Meet some of those leading the field.
The Eddie and Jo Allison Smith Foundation Fund for Focused Ultrasound Treatment of Neurodegenerative Disorders will support research for disorders such as Alzheimer’s disease, Parkinson’s, ALS, and Huntington’s.
Today, April 29, at 12:30pm Eastern, the Foundation will host a live Twitter chat discussing focused ultrasound for Parkinson's disease. Follow along at @FUSFoundation and participate using #ParkinsonsChat.